Advaxis, Inc. to Report 12-Month Survival From Its Phase 2 Study of ADXS-HPV in Women With Recurrent/Refractory Cervical Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company’s lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.